Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,622 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06118047 | Crisaborole Ointment for Skin Toxicity Induced by Cetuximab(COSTIC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06120127 | Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence(IMPROVE) | unknown | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 7, 2023 |
| clinicaltrials |
| NCT04753203 | Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients(ALCAP) | unknown | Phase 1 / Phase 2 | 65 | Korean Cancer Study GroupOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05785325 | RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06089330 | A Study of JMT101 in Patients With Metastatic Colorectal Cancer | unknown | Phase 2 | 102 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Oct 18, 2023 | clinicaltrials |
| NCT03638297 | PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer(PCOX) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06060704 | Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | unknown | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04033107 | High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors | unknown | Phase 2 | 30 | Zhongnan HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04259944 | Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | unknown | Phase 2 | 140 | IFOM ETS - The AIRC Institute of Molecular OncologyOTHER | 2 | Sep 28, 2023 | clinicaltrials |
| NCT05555901 | The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer | unknown | Phase 2 | 116 | Fudan UniversityOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06017141 | Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study | unknown | Phase 2 | 80 | University of Kansas Medical CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06010888 | Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC | unknown | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05957016 | Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer | unknown | Phase 2 | 90 | Third Military Medical UniversityOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT06003998 | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab(INTERACT-II) | unknown | Phase 2 | 85 | Catharina Ziekenhuis EindhovenOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04984369 | The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | unknown | Phase 2 | 50 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04659382 | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer(SIRTCI) | unknown | Phase 2 | 52 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04798612 | Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression(IPOS) | unknown | Phase 2 | 68 | Zealand University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05127759 | The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation | unknown | Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05842525 | Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 2 | 42 | Hunan Cancer HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05911789 | Online Adaptive Radiation Therapy for Rectal Cancer | unknown | Phase 1 / Phase 2 | 15 | Peking Union Medical College HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05970302 | XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC | unknown | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970705 | Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC | unknown | Phase 2 | 101 | Fudan UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05871333 | Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients | unknown | Phase 2 | 80 | Ain Shams UniversityOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT04653480 | Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | unknown | Phase 2 | 61 | Zhejiang UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT02560298 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer(InterAACT) | unknown | Phase 2 | 91 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913570 | Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer(MSI-H/dMMR) | unknown | Phase 2 | 22 | LiuYingOTHER_GOV | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03073694 | Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis | unknown | Phase 2 | 100 | University of Kansas Medical CenterOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05160896 | SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer | unknown | Phase 2 | 90 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05894837 | Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT03831698 | Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) | unknown | Phase 2 | 21 | University of Kansas Medical CenterOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04083365 | Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer(PANDORA) | unknown | Phase 2 | 100 | AUSL Romagna RiminiOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05233332 | Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)(mCRC) | unknown | Phase 2 | 186 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05799820 | QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 25, 2023 | clinicaltrials |
| NCT05868317 | Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer | unknown | Phase 2 | 70 | Salah Azaïz Cancer InstituteOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05382741 | Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial(VIVA) | unknown | Phase 2 | 182 | Ospedale Policlinico San MartinoOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05858567 | Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma(RECMULRA-TNT) | unknown | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05845268 | Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer | unknown | Phase 2 | 102 | Beijing Friendship HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05833672 | Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers | unknown | Phase 2 | 100 | fan liOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05815290 | Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05815303 | XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | unknown | Phase 2 | 92 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05799443 | Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | unknown | Phase 2 | 23 | Fujian Cancer HospitalOTHER_GOV | 0 | Apr 5, 2023 | clinicaltrials |
| NCT01628211 | Second Look Laparoscopy in Colorectal Cancer(HIPEC) | unknown | Phase 2 | 140 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01801904 | A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer(PACER) | unknown | Phase 2 | 52 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01898104 | Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer(V-shoRT-R3) | unknown | Phase 1 / Phase 2 | 152 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02619435 | Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer(STREAM) | unknown | Phase 2 | 46 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03038256 | Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial(EXPLORE) | unknown | Phase 2 | 244 | Peking University People's HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT04194359 | Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer | unknown | Phase 2 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05763927 | Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT | unknown | Phase 2 | 44 | West China HospitalOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05755685 | Hyperthermic Intraperitoneal Treatment of rmhTNF for CRCPM: Phase II Clinical Trial | unknown | Phase 2 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 6, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Nov 7, 2023source: clinicaltrials